Overview

Medivation is currently conducting clinical trials to evaluate Dimebon™ in patients with mild to moderate Alzheimer’s disease and in patients with Huntington’s disease. In addition, a clinical study is underway to assess MDV3100 in the treatment of hormone-refractory prostate cancer.

A confirmatory pivotal Phase 3 trial of Dimebon in patients with mild to moderate Alzheimer’s disease is expected to start in Q208. This trial will enroll patients in the United States, Europe and South America.

Patients and Physicians: If you are interested in participating in or learning more about our Phase 3 Alzheimer’s disease program, please fill out the following form. (* Required fields)

Contact Information

Title
First Name*
Last Name*
Address*
City*
State*	-- Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming Virgin Islands American Samoa Guam
Zip Code*
Phone*	(Include area code)
Email*
Confirm Email*
I am a*	Physician  Caregiver  Patient  Other
Comments

For more information about the Dimebon studies, please contact Medivation at trials@medivation.com.

To learn more about clinical trials, please visit www.clinicaltrials.gov, a service of the U.S. National Institutes of Health.